Tax Cuts Potential Impact on Overseas (ex-US accounts) by Top 9 Biopharma holdings of $133B in M&A
Reporter: Aviva Lev-Ari, PhD, RN
Amgen has been sheltering a cache of about $35 billion in ex-US accounts, according to some numbers that EvercoreISI’s Umer Raffat put together as he began assessing the impact tax reform could have on the top players in overseas holdings.
SOURCE
The top 9 overseas accounts in biopharma hold $133B in M&A firepower by john carroll April 27, 2017 06:42 AM EDT, Updated: 08:15 AM
Leave a Reply